Physician profile
Bonney Collins
NPI 1750145165
$5,623.50
in general payments reported to CMS, 2019-2025
55 companies · $3,029 in 2025
The $3,029 reported for 2025 was more than what 85% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $653 · 2024: $1,942 · 2025: $3,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,685 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,684.98 |
| Education | $285.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $511.86 | 2024-2025 | Vyloy, Padcev, Xtandi |
| Janssen Biotech, INC. | $346.15 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $291.89 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Glaxosmithkline, LLC. | $241.08 | 2024-2025 | Trelegy Ellipta, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $231.19 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $202.02 | 2024-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $196.59 | 2024-2025 | |
| Incyte Corporation | $178.14 | 2024-2025 | Monjuvi, Jakafi |
| Celgene Corporation | $173.35 | 2025 | Opdualag, Reblozyl, Breyanzi |
| Lilly USA, LLC | $149.67 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $142.51 | 2024-2025 | Opdivo, Opdualag |
| Sobi, INC | $127.22 | 2024-2025 | |
| Genentech USA, INC. | $124.34 | 2024-2025 | Polivy, Phesgo, Itovebi |
| Tersera Therapeutics LLC | $123.09 | 2024-2025 | Zoladex |
| Gilead Sciences, INC. | $116.82 | 2025 | Trodelvy |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bonney Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.